Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Izzy who wrote (2451)	10/22/1997 1:36:00 AM
From: JOHN W.	Respond to of 6136

<does anyone know what the estimated European sales will be?> L. Moss addressed Europe today: Subject: Re: Viracept revenues now exceed Merck's Crixivan's in U.S. market Date: Tue, Oct 21, 1997 15:41 EDT From: LMoss Message-id: <19971021194100.PAA06282@ladder01.news.aol.com> I think that the European approval process has moved beyond the CPMP, which I suspect did what it had to do at its previous meeting. The most likely reason for the move upward in stock price, in my opinion, is simply that AGPH is an extremely undervalued stock. My estimate of current intrinsic value is $148/share. (For readers with eagle eyes, this is not a typographical error. My previous estimate of $147/share was based on a slighly longer discount period. The current value will increase about $1/week as the discount rate is applied to a shorter period.) LMoss

To: Izzy who wrote (2451)	10/22/1997 1:39:00 AM
From: JOHN W.	Read Replies (1) \| Respond to of 6136

More from L. Moss today on European sales: Subject: Viracept revenues now exceed Merck's Crixivan's in U.S. market Date: Tue, Oct 21, 1997 14:42 EDT From: LMoss Message-id: <19971021184201.OAA02765@ladder02.news.aol.com> In the third calendar quarter of this year (quarter just ended), Merck's Crixivan had revenues of $71 million in the U.S. This compares with the $75 million achieved by Agouron's Viracept. Viracept U.S. revenues have increased by $31 million in each of the last two quarters. I think it will do a bit better in the current quarter (a $35 million increase), which is why I previously estimated 3QFY98 at $110 million. When Viracept is approved in Europe and elsewhere, there is no reason to believe that it will not soon (within six to nine months) pull ahead of Crixivan in those markets as well. LMoss